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Abstract
The process of aging deeply influences morphological and functional parameters of peripheral nerves. The observations summarized
here indicate that the deterioration of myelin occurring in the peripheral nerves during aging may be explained by the fall of the levels of
the major peripheral myelin proteins [e.g., glycoprotein Po (Po) and peripheral myelin protein 22 (PMP22)]. Neuroactive steroids, such as
progesterone (PROG), dihydroprogesterone (5-DH PROG), and tetrahydroprogesterone (3,5-TH PROG), are able to stimulate the low
expression of these two myelin proteins present in the sciatic nerve of aged male rats. Since Po and PMP22 play an important physiological
role in the maintenance of the multilamellar structure of PNS myelin, we have evaluated the effect of PROG and its neuroactive derivatives,
5-DH PROG and 3,5-TH PROG, on the morphological alterations of myelinated fibers in the sciatic nerve of 22–24-month-old male
rats. Data obtained clearly indicate that neuroactive steroids are able to reduce aging-associated morphological abnormalities of myelin
and aging-associated myelin fiber loss in the sciatic nerve.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
The search for molecules that are able to promote healthy
aging and reverse age-dependent alterations of the nervous
system represents an important goal for biomedical research.
The aim of the present review will be to discuss in partic-
ular the changes occurring in the peripheral nervous sys-
tem (PNS), with a particular focus on myelin of peripheral
nerves and on its protein components. Recent results ob-
tained in our and other laboratories indicating that neuroac-
tive steroids stimulate the expression of myelin proteins of
PNS and are able to counteract the effects of the process of
aging on the myelin compartment of peripheral nerves will
be summarized.
2. Effect of aging on peripheral nerves
The aging process induces important morphological and
functional changes in peripheral nerves. It is well known
that large myelinated fibers undergo atrophy, while myelin
sheaths increase in thickness and show various irregularities
(Thomas et al., 1980; Dyck et al., 1981; Grover-Johnson
and Spencer, 1981; Adinolfi et al., 1991; Johansson et al.,
1996). In the sciatic nerve of normal old cats, anomalies are
characterized by the retraction of the lateral loops adjacent
to the nodes of Ranvier, by vacuolation, by fragmentation or
by the appearance of “bubbles”. At the ultrastructural level,
different stages of demyelination are evident. In particular,
it is possible to observe an accumulation of mitochondria,
lipid-like droplets, as well as heterogeneous granular and
vacuolar materials in the outer cytoplasmic compartment of
Schwann cells, and in the distended portion of the inner
adaxonal rim (Adinolfi et al., 1991). Disruption of one or
more segments of the myelin sheaths also occurs; this dis-
ruption is produced by interlamellar splitting and ballooning
along the major dense line and the intraperiod lines (Adinolfi
et al., 1991). Peripheral nerves of rats show similar morpho-
logical changes (e.g., myelin ballooning, splitting, infold-
ing, reduplication and remyelination) (Knox et al., 1989;
Verdù et al., 2000). We have recently observed that in sciatic
nerve of aged rat the most frequent of these abnormalities
was the presence of myelin infoldings into the axoplasm.
Myelin infoldings were observed in 7% of myelinated fibers
in the nerves of young rats. The proportion of fibers with
myelin infoldings was significantly increased in aged ani-
mals (6.98 ± 0.98% versus 34.55 ± 2.76% of fibers with
myelin infoldings in young and old rats, respectively; P <
0.05). In contrast, myelin outfoldings and abnormalities in
myelin compaction affected less than 2% of the myelinated
fibers and did not significantly increase in aged animals
(Azcoitia et al., 2003).
Other morphological changes imply the relations between
nodal spacing and fiber diameters, which become increas-
ingly variable due to nodal widening, paranodal and/or seg-
mental demyelination accompanied by remyelination (Knox
et al., 1989). Wallerian-type degeneration followed by ax-
onal regeneration and myelination also occur (Lascelles and
Thomas, 1966; Thomas et al., 1980; Grover-Johnson and
Spencer, 1981; Braund et al., 1982a,b; Berthold et al.,
1983; Verdù et al., 2000).
Morphological changes due to aging are also evident in
unmyelinated nerve fibers. For instance, a morphometric
study performed on unmyelinated fibers present in human
sural nerve indicated that the percentage of subunits contain-
ing unmyelinated axons and the mean number of axons in
single axon-containing Schwann cells subunits are signifi-
cantly decreased (Kanda et al., 1991). On the contrary, other
parameters like the density of Schwann cells subunits with
and/or without axons, the single protrusion of Schwann cells,
the collagen pockets, and the mean number of Schwann cells
profiles per axon are significantly increased (Kanda et al.,
1991). A reduction in the number of density of myelinated
fibers has been reported with aging in peripheral nerves of
several animal species (Verdù et al., 2000). In agreement, we
have recently observed that the density of myelinated fibers
is clearly reduced in the sciatic nerve of aged rats: the total
number of myelinated fibers was significantly decreased in
old animals (10,512±751 versus 7328±336 fibers per nerve
in young and aged rats, respectively; P < 0.05) (Azcoitia
et al., 2003). The effect of aging is particularly evident in
myelinated fibers of small caliber. Thus, more than 60% of
the myelinated fibers with a diameter under 5m are lost
in aged animals (2459 ± 182 versus 900 ± 161 fibers per
nerve in young and aged rats, respectively; P < 0.05). The
total number of unmyelinated axons is also significantly re-
duced by aging (16,194± 1742 versus 11,130± 823 axons
per nerve in young and aged rats, respectively; P < 0.05)
(Azcoitia et al., 2003).
Alterations in the size and shape of myelinated fibers also
occur with aging. The majority (>80%) of myelinated fibers
in the sciatic nerve of young rats show a circular or ovoidal
profile in cross-sections. However, lobulated, triangular and
crescent-shaped profiles are also observed (Azcoitia et al.,
2003). The irregular shapes are increased with aging. Thus,
less than 50% of the myelinated fibers in old animals had a
circular or ovoidal profile (17±3% versus 55±3% of fibers
with irregular shapes in young and old rats, respectively;
P < 0.05) (Azcoitia et al., 2003). It is interesting to note
that similar changes have been related to a decrease of neu-
rofilament mRNA levels; as shown by Parhad et al. (1995),
such levels decreased at the levels of rat PNS of about 60%
at 23 months of age.
Moreover, the aging process also affects functional param-
eters. For instance, electrophysiologic studies have shown
that nerve conduction velocity is lower in aged subjects than
in young ones (Verdù et al., 2000). However, the rate of
decline of nerve conduction velocity depends on the type
of fiber (afferent versus efferent), the nerve and the ani-
mal species (Wagman and Lesse, 1952; Norris et al., 1953;
Wayner and Emmers, 1958; Burke et al., 1974; Sato et al.,
1985; Swallow and Griffiths, 1977; Rivner et al., 2001). For
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instance, in aged rats, there is no change in the conduction
velocity of the phrenic nerve until 28 months of age (Smith
and Rosenheimer, 1984), but a decrease in spinal nerve is ev-
ident (Retzlaff and Fontaine, 1965; Koella, 1979). In female
mice, the amplitude of muscle action potentials recorded
from the plantar and tail muscles decreases linearly with age
from 2 to 24 months. Furthermore, the latency of the onset
of the muscle action potential declines from 2 to 6 months,
remains unchanged between 6 and 12 months, and is in-
creased in older mice (Verdù et al., 1996). On the contrary,
the conduction velocity of unmyelinated fibers seems to be
unaffected by the aging process (Sato et al., 1985).
3. Glycoprotein Po and peripheral myelin protein
22: two important myelin proteins of the peripheral
nervous system
Proteins present in the myelin of PNS include glycopro-
tein Po (Po), peripheral myelin protein 22 (PMP22), myelin
basic protein (MBP), myelin-associated glycoprotein and
connexin 32. Among these, Po and PMP22 seem to exert
an important role for the maintenance of the multilamel-
lar structure of PNS myelin. In particular, Po, which ac-
counts for over 50% of PNS myelin protein, is synthesized
by Schwann cells and then predominantly confined to the
compact portion of the mature myelin. Po is a simple in-
tegral membrane glycoprotein, with single transmembrane,
extracellular and cytoplasmic domains, and is a member of
the immunoglobulin gene superfamily (Lemke and Axel,
1985; Sakamoto et al., 1987; Eichberg, 2002). Po is believed
to play a major role in the compaction of normal myelin
serving as a bifunctional structural element linking adjacent
lamellae, and thereby stabilizing the assembly of the myelin
(Lemke, 1986; D’Urso et al., 1990; Snipes and Suter, 1995).
The importance of Po for stabilizing compact myelin
is illustrated by the severe phenotype of Po-negative
mice generated by homologous recombination. They show
abnormal motor coordination, tremors, axon degenera-
tion, and a severe hypomyelination with decompaction of
myelin in very young ages followed by degeneration of
myelin and formation of onion bulbs (Giese et al., 1992;
Martini et al., 1995; Zielasek et al., 1996). With progress-
ing age, these abnormalities become more pronounced (see
Section 5). These pathological alterations resemble those
seen in some dominantly inherited human peripheral neu-
ropathies (e.g., Charcot–Marie-Tooth type 1B, CMT1B, and
Déjérine–Sottas syndrome, DSS).
PMP22, which represents 2–5% of total peripheral myelin
proteins, like Po, is synthesized by Schwann cells and then
confined in the compact myelin (Welcher et al., 1991).
However, unlike Po, which is nerve-specific, PMP22 is ex-
pressed also in other tissues, including lung, gut, and heart
(Welcher et al., 1991; Quarles, 1997; Bronstein, 2000).
Several alterations of the PMP22 gene have been associated
with a set of hereditary peripheral neuropathies in humans
(Charcot–Marie-Tooth type 1A, CMT1A; DSS, and hered-
itary neurophaty with liability to pressure palsies, HNNP)
and with the Trembler and Trembler J alleles in mice (Suter
and Snipes, 1995; Naef and Suter, 1998).
The fact that PMP22 contains the carbohydrate group
HNK1 has suggested that it may have an adhesive function in
myelin (Bronstein, 2000). In fact, it has been demonstrated
that PMP22 and Po may form complexes in the myelin mem-
branes. The interactions between these two proteins proba-
bly participate in holding adjacent Schwann cell membranes
together and in stabilizing myelin compaction (D’Urso et al.,
1999).
4. Neuroactive steroids
In the last decade, several observations have shown that
the capability to synthesize steroid hormones is not only
a feature of classical steroidogenic tissues (e.g., gonads
and adrenals) but may also occur in the nervous system,
forming neurosteroids (Baulieu, 1998; Mellon and Griffin,
2002). Moreover, the nervous system is also able to me-
tabolize neurosteroids into metabolites known as neuroac-
tive steroids. Formation of neurosteroids and neuroactive
steroids seems to take place mainly in the glial compart-
ment, and in the PNS is particularly located in Schwann
cells (Koenig et al., 1995; Melcangi et al., 1992; Guennoun
et al., 1997; Melcangi et al., 1998a; Schumacher et al.,
2001). The PNS is able to form neuroactive steroids via the
enzymatic complex formed by both 5-reductase (5-R)
and 3-hydroxysteroid dehydrogenase (3-HSD) (Melcangi
et al., 1992, 1998a, 1999b, 2001a,b). This enzymatic com-
plex is very versatile, since every steroid possessing the
delta 4-3keto configuration may be first 5-reduced and
subsequently 3-hydroxylated. In particular, testosterone
(T) can be converted into dihydrotestosterone (DHT) and
then into 5-androstane-3,17-diol (3-diol), PROG into
5-DH PROG and subsequently into 3,5-TH PROG and
so on (Melcangi et al., 1999b, 2001b). The 5-R-3-HSD
enzymatic complex is present both in peripheral nerves
(e.g., sciatic nerve) and in Schwann cells in culture. In par-
ticular, the 5-R activity of Schwann cells is higher than
that of oligodendrocytes, their CNS equivalent (Melcangi
et al., 1998a), and similar to that found in fetal neurons
(Melcangi et al., 1990b, 1993, 1994). In contrast, Schwann
cells possess lower 3-HSD activity than oligodendrocytes
(Melcangi et al., 1998a).
Schwann cells not only possess the capability to form
neuroactive steroids but are also a possible target for some
of them. As demonstrated by our own and other laborato-
ries, Schwann cells express mRNA for progesterone recep-
tor (PR) and also the protein itself (Jung-Testas et al., 1996;
Magnaghi et al., 1999, 2001). Moreover, they also express
non-classical steroid receptors, for instance, the GABAA
receptor (Melcangi et al., 1999a). Consequently, Schwann
cells may respond to neuroactive steroids, such as 3,5-TH
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PROG or 3-diol, that are then able to actively interact
with this neurotransmitter receptor (Melcangi et al., 1999b,
2001b).
5. Aging affects myelin protein levels and neuroactive
steroid formation
A clear decrease in the levels of protein Po has been
reported in the sciatic nerve of aged rats (Uchida et al.,
1986), and in human sural nerve (Koski and Max, 1980).
Several observations on the possible effects of aging on
peripheral myelin proteins have been made in knockout
models (Giese et al., 1992; Martini et al., 1995; Zielasek
et al., 1996; Shy et al., 1997; Fruttiger et al., 1995; Nelles
et al., 1996; Scherer et al., 1998). For instance, it has been
demonstrated that mice lacking one of the two Po alleles by
homologous recombination (Po+/−) have the clinical, elec-
trophysiological, and morphological features of acquired
demyelinating neuropathies, such as chronic inflammatory
demyelinating polyneuropathy (CIDP). Po+/− mice are
clinically normal until 5 months of age, when they begin to
develop a “waddling” gait. The gait disorder progresses for
the next 6–8 months and then stabilizes. By 1 year of age,
these mice develop severe, asymmetric slowing of motor
nerves, with temporal dispersion or conduction block. Mor-
phological analysis reveals severe demyelination of motor
fibers, focal regions of demyelination and the presence
of inflammatory cells. All these pathological changes are
even more pronounced at 20 months (Shy et al., 1997). In
humans CIDP is evident between 40 and 60 years of age
(McCombe et al., 1987; Mendell, 1993).
Our studies performed by in situ hybridization and/or
Northern blot analysis have shown that Po, PMP22 and MBP
mRNA levels are all significantly decreased in the sciatic
nerves of aged male rats (Melcangi et al., 1998a,b, 1999a).
Further observations performed by Western blot analysis
have indicated that not only mRNA but also the protein lev-
els of Po and PMP22 proteins are decreased during aging
(Fig. 1).
These observations agree with, and provide a possible ex-
planation for, the findings quoted in Section 2 of this review,
showing that several morphological and functional aspects
of peripheral myelin are profoundly modified during senes-
cence (Spencer and Thomas, 1970; Thomas et al., 1980;
Grover-Johnson and Spencer, 1981; Johansson et al., 1996;
Downie and Newell, 1961; Morales et al., 1987; Adinolfi
et al., 1991; Verdù et al., 1996; Melcangi et al., 2000b; Verdù
et al., 2000).
The aging process also affects formation of neuroac-
tive steroids in peripheral nerves. We have observed that
aging significantly impairs the formation of 5-reduced
metabolites in sciatic nerves of 20-month-old male rats
(Melcangi et al., 1990a, 1992). In contrast, aging seems
not to affect 3-HSD activity (Melcangi et al., 1990a,
1992).
Fig. 1. Effect of aging on the expression of Po and PMP22 in the sciatic
nerve of the male rats (22–24 months old). (A) Representative Western
blot of one experiment performed. (B) Quantitative data, expressed as
percent variation vs. the levels detected in adult (3 months old) male rats
(baseline). The columns represent the mean±S.E.M. of all determinations
performed (numbers in parentheses). ∗∗P < 0.01 vs. baseline.
6. Effects of neuroactive steroids on peripheral myelin
proteins
As mentioned in the previous section, aging is associated
with a decrease in the synthesis of Po and PMP22 (Melcangi
et al., 1998a,b, 1999a, 2000b). Moreover, as mentioned in
Section 4, on the basis of the presence of classical and
non-classical steroid receptors, it is now well known that
PNS and in particular its glial component (i.e., Schwann
cells) represent a possible target for the actions of neuroac-
tive steroids. Consequently, we have evaluated whether neu-
roactive steroids could counteract the drop of Po and PMP22
levels found in the sciatic nerve of aged animals (Melcangi
et al., 1998a,b, 1999a, 2000b). To this end, we have treated
old male rats (22–24 months old) for 1 month with eight
subcutaneous injections of 1 mg of PROG, 5-DH PROG
or 3,5-TH PROG. Injections were administered every 4
days and mRNA levels of Po and PMP22 were evaluated
in the sciatic nerve by Northern blot analysis, 24 h after
the last treatment. Only 5-DH PROG was able to signifi-
cantly increase the mRNA levels of Po. In contrast, PROG
and 3,5-TH PROG were unable to significantly modify
the gene expression of Po (Melcangi et al., 1998a, 1999a).
However, the situation was different when the protein levels
of Po were analyzed by Western blot. As shown in Fig. 2,
not only 5-DH PROG but also its precursor PROG were
able to increase the low protein levels of this myelin pro-
tein present in the sciatic nerve of aged rat, suggesting that
additional post-transcriptional effects are exerted by these
neuroactive steroids on the synthesis of this myelin protein.
R.C. Melcangi et al. / Progress in Neurobiology 71 (2003) 57–66 61
Fig. 2. Effect of in vivo treatment with progesterone (PROG), dihydropro-
gesterone (5-DH PROG) or tetrahydroprogesterone (3,5-TH PROG)
on Po protein levels in the sciatic nerve of aged male rats (22–24 months
old). (A) Representative Western blot of one experiment performed. (B)
Quantitative data expressed as percent vs. the levels detected in aged rats
treated with vehicle only (C). The columns represent the mean± S.E.M.
of all determinations performed (numbers in parentheses). ∗∗P < 0.05 vs.
controls.
A very similar situation is evident for PMP22. In fact, in
vivo treatments with PROG, 5-DH PROG or 3,5-TH
PROG were unable to increase the low mRNA levels of this
myelin protein found in the sciatic nerve of aged male rats
(Melcangi et al., 1999a). However, 3,5-TH PROG was
able to significantly increase PMP22 protein levels in the
sciatic nerve of aged rats (Fig. 3). The effects of PROG
and/or its derivatives on Po and PMP22 are also evident in
other in vivo and in vitro experimental models. For instance,
in the case of Po, in vivo treatments with PROG, 5-DH
PROG and 3,5-TH PROG were all effective in increasing
Po gene expression in the sciatic nerve of adult male rats;
in particular 5-DH PROG was significantly more effective
than the other two steroids (Melcangi et al., 1999a). In the
same experimental model, the mRNA levels of PMP22 were
significantly increased only by the treatment with 3,5-TH
PROG (Melcangi et al., 1999a).
Neuroactive steroids, like PROG and its derivatives, may
increase gene expression of myelin proteins after peripheral
nerve injury. For instance, we have analyzed the possible
effects of PROG and of its 5- and 3,5-reduced metabo-
lites on the gene expression of Po and PMP22 after transec-
tion and entubulation techniques to repair the sciatic nerve
of adult male rat (Melcangi et al., 2000a). The data obtained
Fig. 3. Effect of in vivo treatment with progesterone (PROG), dihydropro-
gesterone (5-DH PROG) or tetrahydroprogesterone (3,5-TH PROG)
on PMP22 protein levels in the sciatic nerve of aged male rats (22–24
months old). (A) Representative Western blot of one experiment per-
formed. (B) Quantitative data expressed as percent vs. the levels detected
in aged rats treated with vehicle only (C). The columns represent the
mean±S.E.M. of all determinations performed (numbers in parentheses).
∗∗P < 0.05 vs. controls.
indicate that after an experimental period of 2 weeks, both
PROG and 5-DH PROG are able to significantly increase
the low Po mRNA levels present in the distal portion from the
cut of the sciatic nerve (Melcangi et al., 2000a). These find-
ings are in agreement with the results obtained on the basal
levels of Po present in the intact sciatic nerve of adult ani-
mals (Melcangi et al., 1999a). However, at variance to what
was observed in the intact sciatic nerve, 3,5-TH PROG
was ineffective in stimulating Po mRNA levels in this experi-
mental model (Melcangi et al., 2000a). Moreover, 3,5-TH
PROG did not alter PMP22 mRNA levels (Melcangi et al.,
2000a), suggesting that the mechanisms by which this neu-
roactive steroid exerts its effect on the gene expression of
these myelin proteins might be altered after peripheral nerve
injury. Beneficial effects of PROG and pregnenolone have
been also demonstrated by Koenig et al. (1995) who showed
that both steroids, when given locally, are able to counteract
the decrease of the amounts of myelin membranes induced
by a cryolesion in the sciatic nerve of the mouse.
Further experiments performed in our laboratory have
indicated that the effects of PROG, 5-DH PROG and
3,5-TH PROG on Po and/or PMP22 gene expression are
also evident when cultures of rat Schwann cells are used.
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In agreement with the in vivo results on the intact sci-
atic nerve of adult male rats, PROG, 5-DH PROG and
3,5-TH PROG in the case of Po, and 3,5-TH PROG
in the case of PMP22, exert a stimulatory effect on gene ex-
pression of these myelin proteins (Melcangi et al., 1998a,
1999a). Moreover, as shown by Désarnaud et al. (1998),
PROG also stimulates Po gene expression in a different
experimental model (Schwann cells transiently transfected
with a reporter construct in which the luciferase expression
is controlled by the promoter region of the Po gene). How-
ever, at variance with our observations, these authors have
found that PROG is also able to stimulate the gene expres-
sion of PMP22. In this connection, it is also relevant that in
Schwann cells co-cultured with dorsal root ganglia neurons
PROG is able to accelerate the time of initiation, and to en-
hance the rate of myelin synthesis (Chan et al., 1998, 2000).
The data so far mentioned clearly indicate that PROG
and/or its derivatives, 5-DH PROG and 3,5-TH PROG,
are able to stimulate the expression of Po and the PMP22.
However, they also suggest that the mechanisms involved
in these effects are different. Thus, in the case of Po, it is
possible that the effects of PROG and 5-DH PROG might
directly involve the PR, which is present both in the sci-
atic nerve and in cultured Schwann cells (Jung-Testas et al.,
1996; Magnaghi et al., 1999, 2001). Moreover, in view of
the higher efficacy of 5-DH PROG, it is also possible
to hypothesize that the conversion of PROG into 5-DH
PROG, by 5-R present in the sciatic nerve and in Schwann
cells (Melcangi et al., 1992, 1999b, 2001a,b), is a neces-
sary step. Furthermore, since the activity of the 3-HSD is
bi-directional (Celotti et al., 1992; Melcangi et al., 1999b,
2001b), it is possible to assume that the efficacy of 3,5-TH
PROG, which is not able to directly bind to the PR, may
result from a retro-conversion of this steroid into 5-DH
PROG. On the other hand, since 3,5-TH PROG is a
well-known ligand of the GABAA receptor (Celotti et al.,
1992; Melcangi et al., 1999b, 2001b), also a direct effect
of this steroid via the interaction with this neurotransmitter
receptor cannot be excluded. As previously mentioned, we
have shown that GABAA receptor is expressed both in sciatic
nerve and in Schwann cell cultures (Melcangi et al., 1999a).
The situation is different in the case of PMP22, since only
3,5-TH PROG is effective, and consequently a possible
effect via the GABAA receptor might be taken in considera-
tion. Recently, we have investigated these mechanisms using
agonists and antagonists of PR and GABAA receptor. The
data obtained have indicated that, at least in cultures of rat
Schwann cells, Po is under the control of PR, while PMP22
depends on the GABAA receptor (Magnaghi et al., 2001).
An effect on Po through the PR might be also supported by
the identification of some progesterone-responsive elements
(PRE) on the Po promoter (Magnaghi et al., 1999).
The finding that PROG and/or its derivatives are able to
influence the expression of Po and PMP22 in the sciatic
nerve of aged rats seems to be a peculiarity of these neu-
roactive steroids. In fact, T and its derivatives, DHT and
3-diol, are totally unable to modify the synthesis of these
two myelin proteins (Melcangi et al., 2000b). However, the
situation is different when other in vivo (adult male rats) or
in vitro (rat Schwann cells) experimental models are con-
sidered. For instance, in adult male rats, castration clearly
decreases the Po mRNA levels in the sciatic nerve by about
40%, and systemic administration of DHT is able to increase
the levels of the messenger of this myelin protein (Magnaghi
et al., 1999). Since, at variance to what happens with PR,
Schwann cells seem not to express androgen receptor (AR)
(Magnaghi et al., 1999), we have hypothesized that in our in
vivo experiments, the gene expression of Po is stimulated by
androgen-dependent mechanisms acting on Schwann cells
in an indirect fashion. For instance, androgens might act
through the neuronal component, which does contain AR
(Magnaghi et al., 1999; Jordan et al., 2002). However, with
similar treatments in cultures of rat Schwann cells, we have
observed that DHT is able to increase the Po mRNA levels
(Magnaghi et al., 1999). Consequently, we have tested the
hypothesis that DHT might be able to activate Po gene ex-
pression by acting through a steroid receptor other than the
AR. Since, as mentioned above, 5-DH PROG, a steroid
that interacts with the PR, may activate Po gene expression
(Melcangi et al., 1998a, 1999a), we have postulated that
DHT might interact with the PR, and activate PRE. The data
so far obtained indicate that, in a human neuroblastoma cell
line (SK-N-MC) co-transfected with the hPRB and with a
reporter plasmid containing a PRE, DHT is able to exert a
transcriptional activity via the human PR (Magnaghi et al.,
1999). Therefore, in addition to a neuronal mediated effect
on Po gene expression, a co-operation between progestagens
and androgens might be hypothesized.
Moreover, not only the gene expression of Po but also
that of PMP22 seems to be modulated by T derivatives.
We have observed that, in cultures of rat Schwann cells,
3-diol is able to significantly increase PMP22 mRNA lev-
els (Magnaghi et al., 2001). This observation is interest-
ing because of its similarity with the efficacy of 3,5-TH
PROG on the same protein (Melcangi et al., 1999a). It has
been proposed that 3-diol, which does not bind to the AR,
might interact with GABAA receptor (Gee et al., 1988; Frye
et al., 1996). Consequently, these observations further sup-
port the concept that the PMP22 mRNA levels are stimu-
lated in Schwann cells via the GABAA receptor.
7. Effects of neuroactive steroids on morphology of
peripheral myelin
On the basis of the effects exerted by neuroactive steroids
on Po and PMP22 expression, we have evaluated whether
pharmacological treatments with neuroactive steroids may
prevent or counteract aging-associated morphological al-
terations of peripheral nerves. To this purpose, using the
same in vivo experimental protocol mentioned in the previ-
ous section, we have analyzed the possible effect of PROG,
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Fig. 4. Representative photomicrographs from the sciatic nerves of a adult rat (a) and of aged rats (22–24 months old) treated with vehicle only (b),
progesterone (c), testosterone (d), dihydroprogesterone (e), dihydrotestosterone (f), tetrahydroprogesterone (g) or 3-diol (h). All figures are at the same
magnification. Scale bar, 25m.
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5-DH PROG and 3,5-TH PROG on different morpho-
logical parameters of the myelin compartment of sciatic
nerve of 22–24-month-old male rats. In a parallel exper-
iment, the possible effects of T and its derivatives, DHT
and 3-diol, have been also analyzed. Data obtained by
treatment with PROG, 5-DH PROG or 3,5-TH PROG
indicate that these neuroactive steroids have clear effects
on the number and shape of myelinated fibers as well as
on the frequency of myelin abnormalities (Azcoitia et al.,
2003). In particular, one of the most striking effects of
PROG, 5-DH PROG and 3,5-TH PROG is on myeli-
nated fibers of small caliber (<5m) with a significant in-
crease in their number (Fig. 4). In contrast, the number
of myelinated fibers of a size larger than 5m is not sig-
nificantly affected by the treatment with these neuroactive
steroids. The increase in the number of small myelinated
fibers after neuroactive steroid treatment is accompanied
by a decrease of similar magnitude in the number of un-
myelinated axons and, in particular, to large (>3m) un-
myelinated axons. Thus, sciatic nerves from rats treated with
PROG or its derivatives show a significant decrease in the
number of large unmyelinated axons compared to animals
treated with vehicle (1746 ± 119, 450 ± 65, 675 ± 46 and
560± 66 axons in rats treated with vehicle, PROG, 5-DH
PROG and 3,5-TH PROG, respectively; P < 0.05). Fur-
thermore, the g ratio of small myelinated fibers is signifi-
cantly increased by PROG or its derivatives. This suggests
that the increase in the number of myelinated fibers reflects
an increased remyelination of small fibers in aged sciatic
nerves.
Another marked effect of the treatments with PROG,
5-DH PROG and 3,5-TH PROG is the reduction in the
frequency of axons with myelin abnormalities. This effect
is mainly due to a reduction in the frequency of axons with
myelin infoldings, which decreases from 34.6 ± 2.8% of
the axons in animals treated with vehicle to 12.1 ± 1.4,
12.1± 1.1 and 20.9± 2.8% in PROG-, 5-DH PROG- and
3,5-TH PROG-treated animals, respectively. Moreover,
PROG reduces the proportion of fibers with irregular shapes.
As mentioned before, myelin abnormalities and irregular
fiber profiles are typical markers of the aging process in
peripheral nerves (Ceballos et al., 1999; Verdù et al., 2000).
Therefore, our data indicate that PROG, 5-DH PROG and
3,5-TH PROG are able to reduce morphological changes
associated with aging in the sciatic nerve.
The effects on the morphology of myelinated compart-
ment of sciatic nerve of aged male rat so far mentioned
seem to be a peculiarity of PROG and its derivatives. Nei-
ther T nor DHT or 3-diol is able to influence the morpho-
logical parameters analyzed in these experiments (Fig. 4)
(Azcoitia et al., 2003). This situation is similar to the expres-
sion of myelin proteins in the sciatic nerve of aged male rat
(Melcangi et al., 1998a,b, 2000b). Also in that case, while
PROG and its derivatives are effective in increasing the low
expression of Po and PMP22, T and its derivatives seem to
be completely devoid of such effects.
8. Conclusions
The data summarized in the present review indicate that
morphological and biochemical parameters of the myelin
compartment of peripheral nerve are deeply influenced by
the aging process. Interestingly, aging-associated alterations
may be counteracted by the treatment with particular neu-
roactive steroids. Thus, neuroactive steroids are promising
agents to prevent age-associated disorders of peripheral
nerves. This new concept, when verified in other experi-
mental models, might be extended to pathological situations
such as demyelinating diseases (e.g., CMT1A, CMT1B,
HNNP, DSS), peripheral nerve injury or diabetic neurophaty.
Neuroactive steroids may thus represent useful therapeutic
approaches to maintain peripheral nerve integrity.
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